Introduction: There is no consensus on the specific indications for weaning critically ill patients with acute kidney injury (AKI) off renal replacement therapy (RRT). This study aimed to explore the prognostic value of several biomarkers measured upon discontinuation of RRT for their value in predicting 60-day survival and renal recovery in an effort to add knowledge to the decision-making process regarding RRT withdrawal.
INTRODUCTION
Renal replacement therapy (RRT) is essential for the treatment of severe acute kidney injury (AKI). AKI requiring RRT presents a higher in-hospital mortality rate of approximately 50%-80% in the intensive care unit (ICU) and is associated with long-term chronic kidney disease.
1,2 An analysis of AKI patients showed the withdrawal of life support in 72% of deaths. 3 Therefore, it is important to discontinue RRT at the optimal time to improve prognosis. The 2012 Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guidelines for AKI indicate that RRT should be discontinued when intrinsic renal function has adequately recovered or when RRT is no longer consistent with the goals of care. 4 However, the indications for weaning patients off RRT remain obscure, and there is no consensus on this topic. Physicians usually make the decision to withdrawal RRT by referencing conventional parameters, including serum creatinine (sCr), urine output (UO), and electrolyte and volume status. 5 However, these parameters can be affected by multiple factors, some of which do not directly reflect renal repair and prognosis.
Emerging biomarkers, conversely, have been shown to be sensitive, specific, and causally related to the pathogenesis and development of AKI. 6 Some studies have proposed novel biomarkers including osteopontin (OPN), interleukin-6 (IL-6), cystatin C (CysC), interleukin-18 (IL-18), and neutrophil gelatinase-associated lipocalin (NGAL) before the initiation of RRT as prognostic factors for AKI. [7] [8] [9] However, these biomarker levels may change with renal and systemic repair after the RRT procedure. To date, no study has explored the association between biomarkers upon discontinuation of RRT and clinical outcomes.
The aim of the current study was to determine the role of biomarkers, besides conventional indicators such as sCr and UO, following the discontinuation of RRT. The biomarkers associated with 60-day survival and renal recovery were validated to increase the current knowledge regarding the decision-making process for RRT withdrawal in critically ill patients with AKI.
METHODS

Study design and participants
We conducted a prospective observational study in specialized and mixed ICUs of the West China Hospital of Sichuan University, China, which is a tertiary teaching hospital. Consecutive patients who met the Acute Kidney Injury Network (AKIN) criteria 10 and had received acute RRT and had been weaned from this therapy were recruited. The analysis did not include patients who died or were transferred to another hospital while still on RRT. For patients with pre-existing chronic renal insufficiency, AKI was defined as increase of sCr !1 mg/dL from baseline within 48 hours. 11 Patients who were <18 years of age, had received RRT in the last 5 years preceding the index course of disease, underwent renal transplantation, developed AKI from urinary tract obstruction or were weaned from RRT according to a family request were excluded from the study. To investigate the survival rate of patients who were free from RRT during follow up, patients who required acute reinitiation of RRT within 60 days after withdrawing were also excluded.
The study was approved by the Research Ethics Committee of the West China Hospital of Sichuan University and was performed in accordance with the 1964 Helsinki Declaration. Written informed consent was obtained from all conscious participants or the legal representatives of all unconscious participants.
The patients received continuous renal replacement therapy or extended daily dialysis, extended hemodialysis or hemodiafiltration for 6-24 hours per session 12 according to the severity of the disease. Some patients were then selected to receive intermittent hemodialysis when their conditions were significantly associated with remission. The criteria for withdrawing RRT were a trend toward decreasing sCr, UO !400 mL/24 hours, and improved fluid overload, electrolyte and metabolic status.
The primary outcome was 60-day survival, and the secondary outcome was renal recovery at 60 days. Renal recovery was defined as a sCr level no more than 0.5 mg/ dL above the baseline value. 1 
Sample and data collection
Blood and urine samples were collected 1 day after the last session of RRT to reduce the influence of the filter clearance effect. The samples were centrifuged immediately after collection at 1500 rpm for 10 minutes, and the supernatant was frozen at 2808C before analysis. Serum osteopontin (sOPN), serum interleukin 18 (sIL-18), serum neutrophil gelatinase-associated lipocalin (sNGAL), urinary interleukin , and urinary neutrophil gelatinase-associated lipocalin (uNGAL) were measured by sandwich enzyme-linked immunosorbent assay (ELISA) (Cusabio Biotech, Wuhan, China). Serum interleukin 6 (sIL-6) was also measured by sandwich ELISA (Proteintech, Chicago, IL). Serum CysC (sCysC) was measured with an immunoturbidimetric assay (Roche, Basel, Switzerland), according to the manufacturer's instructions. Of note, urinary creatinine (uCr) levels were tested, and urinary biomarker levels were standardized to uCr to minimize individual differences. 13 All sample measurements were performed by investigators blinded to the patient information.
The following clinical information and variables were prospectively collected: demographics, comorbidities, etiologies, AKI stages, severity of illness scores, need for mechanical ventilation, UO, sCr, estimate glomerular filtration rate (eGFR), RRT details and duration of stay in the ICU. The patients were followed up for 60 days after the discontinuation of RRT via clinic consultation or telephone interview.
Data analyses
The variables were expressed as the mean 6 SD, median, or percent frequency, as appropriate. The primary comparison was performed between 60-day survivors and nonsurvivors. Continuous variables were analyzed with the Student's t-test or Mann-Whitney U-test. Categorical variables were analyzed by v2 test. Baseline characteristics that were associated with the outcome of interest (P 0.10) on univariate analysis and all biomarkers and conventional indicators (UO and sCr) upon discontinuation of RRT were included in a multivariate logistic regression analysis. The enter method was applied to obtain factors that were independently associated with 60-day survival. The model fit was evaluated using the Hosmer-Lemeshaw goodness-of-fit test. The levels of independent biomarker predictors were expressed as tertiles, with the lowest tertile considered as the reference group.
14 Receiver operating characteristic (ROC) curve analysis was performed to assess the predictive ability of all biomarker levels as well as conventional indicators for 60-day survival and renal recovery. Net reclassification improvement (NRI) and the integrated discriminative index (IDI) 14, 15 were calculated to quantify the improvement in 60-day mortality risk prediction after the addition of independent biomarker predictors to the clinical model. The clinical model was comprised of age, sex, pre-existing renal impairment, diabetes, Charlson Comorbidity Index (CCI), Acute Physiological and Chronic Health Charlson Comorbidity Index Evaluation (APACHE) II score, sCr and UO upon initiation of RRT, mode of RRT, days of total RRT sessions, and sCr and UO upon discontinuation of RRT. The cut-off values of good predictors were calculated by acquiring the best Youden index. To obtain the combination of biomarkers and conventional indicators with the best predictive value for survival, the variables were added one-by-one to the ROC analysis in the descending order of individual AUCs (area under the curve). The AUC results for different combinations were based on the estimated risk scores obtained from a logistic regression model, which included different variables as covariates. 16 The variables were considered to be statistically significant at P < 0.05. Statistical analyses were performed with SPSS version 22.0 (SPSS Inc., Chicago, IL) and R 2.12.1 (R Foundation for Statistical Computing, Vienna, Austria).
RESULTS
Patient characteristics
One hundred and two patients were enrolled in this study ( Figure 1 ). The mean age was 55.7 years, and 55.9% of the patients were male. Twelve patients had pre-existing renal impairment, but none of the patients had previously developed end-stage renal disease or had been admitted to the ICU for chronic kidney disease. A total of 69 (67.6%) patients survived to day 60, and 50 (72.5%) of these patients showed recovered renal function. The baseline clinical characteristics and parameters upon initiation of RRT are shown in Table 1 . Compared with the non-survivor group, there was a lower prevalence of diabetes (P < 0.001) and stage 2 AKI (P 5 0.021), lower CCI 17 (P 5 0.008), and APACHE II scores (P < 0.001), a lower proportion of patients requiring mechanical ventilation (P 5 0.034), a higher proportion of patients receiving vasopressor (P 5 0.044) and additional days of RRT sessions (P 5 0.012) in the survivor group. We compared biomarker levels between the survivors and nonsurvivors ( Figure 2 ). The levels of sOPN, sIL-6, and sIL-18 of the survivors were significantly lower than those of nonsurvivors (P < 0.001, P < 0.001, and P 5 0.05, respectively). The median levels of sCysC, sNGAL, uIL-18, uNGAL, and uCr in the survivors were also lower, although these results did not reach statistical significance.
Factors related to 60-day mortality
We performed a logistic regression analysis using the enter method, and the independent prognostic factors for 60-day mortality included sOPN (odds ratio Figure 3 ).
Prognostic performance of biomarkers upon discontinuation of RRT for 60-day survival
We performed ROC curve analysis to assess the predictive accuracy of individual and combined biomarkers upon the discontinuation of RRT for 60-day survival ( Table 2 ). All of the variables negatively predicted survival except for UO. For individual biomarkers, sOPN was a moderate to strong predictor for survival and showed the greatest AUC of 0.812 (P < 0.001). The addition of the sOPN level to the clinical model resulted in a significant NRI of 0.453 (P 5 0.026) and an IDI of 0.155 (P 5 0.032). sOPN significantly improved the prediction of 60-day survival beyond the clinical model. Serum IL-6 also showed a moderate predictive value (AUC 0.741, P < 0.001). The best cut-off values of sOPN and sIL-6 were 75.63 ng/mL and 95.82 pg/mL (sensitivity, 0.818 and 0.606; specificity, 0.739 and 0.942), respectively. In general, the biomarkers performed better than the conventional indicators in predicting survival. When combining all of the biomarkers, UO, uCr and sCr, the greatest AUC reached 0.882 (P < 0.001). Figure 4 shows the ROC curve of the best two single and combined biomarkers for predicting survival.
Prognostic performance of biomarkers upon discontinuation of RRT for 60-day renal recovery
Of the 69 cases of survival, 50 (72.5%) patients showed renal recovery at day 60. We also examined the AUC of the biomarkers and conventional indicators for the prediction of renal recovery ( Table 3 ). All of the variables negatively predicted renal recovery except for sOPN and UO. Both the AUCs of sCysC and UO peaked at 0.743 (both P 5 0.002). The best cut-off value for sCysC was 2.47 mg/L (sensitivity 0.947, specificity 0.540). sCr also performed better than the other biomarkers except for sCysC.
DISCUSSION
Discontinuation of RRT in AKI has not been adequately studied. 4 Successful discontinuation should be associated with good prognosis. Specific biomarkers have been associated with renal injury and recovery, and these biomarkers have become the hot spots of research in recent years. 6, 11, 16, 18 This preliminary study explored the prognostic value of biomarkers upon discontinuation of RRT in critically ill patients with AKI, and the results show that sOPN was independently predictive of 60-day survival. Elevated levels of sOPN were independently associated with an increased risk for 60-day mortality, and sOPN provided additional prognostic information beyond the clinical model; sIL-6 was moderately predictive for 60-day survival, and sCysC was moderately predictive for 60-day renal recovery. When combining biomarkers with conventional indicators, the prognostic value for survival became even stronger. Samples in most previous biomarker studies were collected at the time of enrollment or upon commencement of RRT. 7, 8, 11 This study is the first to test biomarkers specifically upon successful discontinuation of RRT for their ability to predict mid-to-long-term survival and renal recovery.
As a promising biomarker in AKI research, OPN is a 44 kD glycoprotein mostly present in the loop of Henle and distal nephrons in the normal kidney. OPN expression is significantly up-regulated in all nephrons after acute injury. 19 Persy et al. 20 found that macrophage infiltration was significantly diminished in the renal tissue of OPNknockout mice with AKI, indicating that OPN may play a role in macrophage-mediated renal injury. Additionally, OPN is related to the proliferation and regeneration of renal cells. 19 Furthermore, OPN has been reported as a pro-inflammatory factor responsible for promoting IL-6 secretion in sepsis and systemic inflammatory response syndrome (SIRS) and is associated with mortality. 21 In this study, we found that OPN was the biomarker with the highest predictive value for death. Lorenzen et al. 7 measured sOPN in 109 critically ill patients with AKI upon the initiation of RRT and 4 weeks after RRT and found that OPN levels at 4 weeks after initiation dramatically declined in patients who successfully discontinued from RRT (P 5 0.0005), whereas the OPN levels did not change significantly in patients who remained dependent on RRT. Moreover, no OPN was detected in spent dialysate, indicating that OPN was not cleared by the treatment procedure. These authors also found that a lower OPN level upon initiation of RRT was independently predictive for 28-day survival (P < 0.0001) with an AUC value of 0.82 (95% CI 0.74-0.89). Combining these results with our findings, we propose that sOPN collected upon the initiation and discontinuation of RRT represents a promising biomarker for predicting survival. When sOPN was combined with other biomarkers, the predictive value for mortality did not improve beyond that of sOPN alone. Thus, from a cost aspect, we suggest that sOPN should be considered as one of the most preferred biomarkers in clinical practice for critically ill patients with AKI.
IL-6 is a major pro-inflammatory mediator in the inflammatory response following acute renal damage. 22 In critically ill patients with AKI, sIL-6 levels can increase as part of both the systemic and kidney-specific inflammatory response, while IL-6 can be slightly cleared during hemofiltration. 23 Simmons et al. 11 measured sIL-6 in AKI patients in the ICU at weekly intervals and found that sIL-6 presented a decreasing trend (P 5 0.01), with the IL-6 levels of survivors remaining lower than those of non-survivors (P 5 0.001). This phenomenon was not affected by whether patients received RRT, demonstrating that sIL-6 during treatment may be predictive for survival. These results are in line with ours, showing that upon discontinuation of RRT, sIL-6 was moderately predictive for 60-day survival but was not an independent predictor. IL-18 is a relatively small molecule contributing to tubular injury in the ischemic kidney. 24 Upon commencement of RRT, IL-18 has been reported to be an independent predictor of hospital mortality in AKI patients (P < 0.001) 25 ; however, we did not find that IL-18 showed remarkable prognostic value upon discontinuation of RRT. We speculate that IL-18 may be partially cleared by a filter membrane and that its secretion can be stimulated as a consequence of bioincompatibility, 26 thus making the serum and uIL-18 levels not sufficiently stable to predict prognosis. NGAL was found to be poorly predictive for 60-day survival and renal recovery, which is consistent with the only 2 previous studies whose samples were collected at similar time points as ours. 16, 18 During hemofiltration, the sieving coefficient of NGAL is 0.2-0.4, 27 which may be a contributing factor for its poor predictive value.
We speculate that 60-day survival following AKI is more closely associated with sOPN and sIL-6 because survival is more related to systemic inflammatory status rather than renal status, and these two biomarkers are secreted more in response to sepsis or SIRS than AKI. Moreover, OPN and IL-6 are both relatively larger molecules and are thus less influenced by filter clearance, making them more accurate predictors of survival.
CysC is the only candidate functional marker of AKI to replace sCr with a much larger molecular weight. 28 The level of CysC was observed to be relatively stable during continuous venovenous hemofiltration, suggesting that CysC can be used to monitor residual renal function during and immediately after RRT. 29 Upon the initiation of RRT, serum CysC has been reported to be predictive of short-term renal function recovery (P < 0.01), 30 and it is not surprising that sCysC showed the greatest AUC value for predicting renal recovery in our study. Uchino et al. 5 found that UO was the most important predictor of successful discontinuation of RRT (AUC 0.808). We found similar results for UO and sCysC. With the exception of sCysC, we did not observe other good biomarkers for 60-day renal recovery; one reason may be that most survivors from critical illness with AKI do finally recover from renal injury, 31 as AKI is only a transient complication to the primary disease. Additionally, with many confounding factors, biomarkers from a single time point may not be closely associated with renal status over the relatively long time span of 60 days. Serum CysC and conventional indicators may remain the best predictors of mid-to-longterm renal recovery. Given the clinical uncertainty and high complexity of disease status, even modest improvements in prognostic biomarkers may be clinically important.
Unfortunately, besides the biomarkers mentioned above, we did not measure the level of tissue inhibitor of metalloproteinase-2 (TIMP-2)ÁIGF-binding protein-7 (IGFBP7), which is the most promising biomarker in the field. A subsequent analysis of the SAPPHIRE study showed that a higher TIMP-2ÁIGFBP7 level early at ICU admission was associated with an increased risk of allcause mortality and/or receipt of RRT at 9 months, specifically in patients who developed AKI (compared with levels <0.3: HR 1.44, 95% CI 1.00-2.06 for levels >0.3 to 2.0, p 5 0.05 and HR 2.16, 95% CI 1.32-3.53 for levels >2.0, p 5 0.002). 32 Biomarkers measured early in the setting of critical illness could predict the development of AKI, the need for RRT and long-term prognosis, which is more useful on a clinical basis than biomarkers measured at the discontinuation of RRT.
This study also has some other limitations. First, this was an observational study without intervention at a single center, and the data may have deviations. Second, we did not test urinary OPN for its predictive value, and the species of biomarkers tested were limited. However, to our knowledge, this study is the first to examine biomarkers specifically upon the successful discontinuation of RRT. In addition, the follow-up time was relatively long, and the study endpoint was 60-day survival and renal recovery, rather than 7 days according to the traditional definition of successful weaning. 5 In summary, our preliminary study indicated that serum and urinary biomarkers upon discontinuation of RRT may be predictive for 60-day survival and renal recovery in critically ill patients with AKI. In particular, sOPN was independently associated with 60-day survival and provided additional prognostic information beyond the clinical model. sIL-6 showed moderate predictive value for 60-day survival, and sCysC was moderately predictive for 60-day renal recovery. Thus, on the basis of significant improvement in azotemia, oliguria, electrolyte disorder and acidosis, discontinuing RRT when the values of sOPN, sIL-6, and sCysC are less than 75.0 ng/mL, 95.0 pg/mL, and 2.50 mg/L, respectively, might be associated with better clinical outcomes. Larger, randomized, multiple-center studies involving more biomarkers are needed to explore the role of various biomarkers for successful discontinuation of RRT with better clinical outcomes.
